TWi Biotechnology (ROCO:6610) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TWi Biotechnology Debt-to-Equity?

TWi Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$2.37 Mil. TWi Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$5.60 Mil. TWi Biotechnology's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$341.04 Mil. TWi Biotechnology's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TWi Biotechnology's Debt-to-Equity or its related term are showing as below:

ROCO:6610' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.03
Current: 0.02

During the past 11 years, the highest Debt-to-Equity Ratio of TWi Biotechnology was 0.03. The lowest was 0.01. And the median was 0.02.

ROCO:6610's Debt-to-Equity is ranked better than
87.93% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6610: 0.02

TWi Biotechnology Debt-to-Equity Historical Data

The historical data trend for TWi Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TWi Biotechnology Debt-to-Equity Chart

TWi Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.03

0.02

0.01

0.02

TWi Biotechnology Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.01	0.01	0.02

Competitive Comparison of TWi Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, TWi Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TWi Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TWi Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TWi Biotechnology's Debt-to-Equity falls into.

TWi Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TWi Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.368	+	5.603)	/	341.038
	=	0.02

TWi Biotechnology's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.368	+	5.603)	/	341.038
	=	0.02

TWi Biotechnology (ROCO:6610) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TWi Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TWi Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TWi Biotechnology (ROCO:6610) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TWi Biotechnology Inc (ROCO:6610) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494

Website

http://www.twibiotech.com

TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.

TWi Biotechnology (ROCO:6610) Headlines

No Headlines